Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Harris Associates International Equity Strategy. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+49.3%
YTD+32.92%
Annualized+0.0907%
Positioning StanceCONSTRUCTIVE
Market CapLarge Cap
Digest Analysis
Quick Take
"Actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stock paradigm begins to unwind."
Executive Summary
For the quarter ending December 31, 2025, the Oakmark International Strategy returned 4.93% (net of fees), slightly underperforming the MSCI World ex USA Index's return of 5.20%. Key contributors to quarterly performance included Bayer, DSV, and Samsung Electronics, while Alibaba Group, CNH Industrial, and Dassault Systemes acted as primary detractors. The fund actively deployed capital by initiating five new large-cap positions (AstraZeneca, IMCD, Sanofi, Symrise, and Unilever) during market pullbacks and fully eliminated eight existing holdings. Management remains confident in international value strategies, noting that the long-standing paradigm of U.S. growth outperformance showed signs of unraveling in 2025, leaving a favorable valuation spread for European and international equities.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
80%
CautiousHigh
High Conviction (80%)
High-conviction positioning: The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...
Growth Outlook
70%
BearishBullish
Bullish (70%)
Market outlook remains above average conviction: The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...
Risk Appetite
70%
DefensiveAggressive
Balanced (70%)
Risk appetite posture is above average conviction: The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...
Capital Deployment
80%
De-riskingDeploying
Deploying (80%)
Manager actively deployed capital into high-conviction opportunities. The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...
Forward Guidance
50%
CautiousExpansionary
Neutral (50%)
Forward guidance signal: The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...
Language Signal
70%
BearishBullish
Bullish (70%)
Tone analysis indicates above average conviction language: The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...
Perceived Risk
40%
Low RiskElevated
Moderate Risk (40%)
Perceived risk level is evaluated as moderate conviction. The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...
Opportunity Density
80%
ScarceAbundant
Abundant (80%)
Opportunity density index indicates high conviction actionable entry points. The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...
Time Horizon
80%
Short-TermLong-Term
Decade+ (80%)
Investment time horizon reflects a high conviction orientation. The Oakmark International Strategy returned 4.93% net in Q4 2025, actively shifting capital into discounted high-quality names like AstraZeneca and Unilever as the U.S. growth-stoc...